No material company-specific disclosures were available in recent briefings at the time of this report's generation. The analysis below draws on SEC filings, Form 4 insider transaction data, and prevailing macroeconomic indicators as of the generation date of 2026-06-04 [Brief - 2026-05-27].
Gilead Sciences reported trailing twelve-month revenue of $29.74 billion as of 31 March 2026, representing year-over-year growth of 4.4%. Net income over the same period stood at $9.22 billion, with a net margin of 31.0% and an operating margin of 34.9%. Gross margin was recorded at 66.5%. Earnings per share grew 54.8% year-over-year on a TTM basis. The company held $7.63 billion in cash against total debt of $23.49 billion. Market capitalisation was approximately $160.2 billion, with a price-to-earnings ratio of 17.55 [SEC 10-Q - GILD - 2026-03-31].
Insider activity is the primary trigger for this report. Ten transactions were recorded over the past 30 days, with a net directional bias toward selling and a net disposal value of approximately $6.04 million [SEC Form 4 - GILD - 2026-06]. No notable 13F institutional holding changes were available in the provided context for this reporting period.
The prevailing macroeconomic backdrop shows the 10-year US Treasury yield at 4.46% and the 2-year yield at 4.05%, producing a normal yield curve with a spread of 41 basis points [FRED DGS10] [FRED DGS2]. This rate environment is a contextual factor for large-cap healthcare companies carrying significant debt obligations, as Gilead's $23.49 billion in total debt is denominated and serviced within this interest rate context.